Alzheimer's disease (AD) remains a major cause of morbidity and mortality worldwide, and
despite extensive research, only a few drugs are available for management of the disease …

The M1 muscarinic acetylcholine receptor (mAChR) plays a crucial role in learning and
memory processes and has long been identified as a promising therapeutic target for the …

The degeneration of cholinergic neurons and cholinergic hypofunction are pathologies
associated with Alzheimer's disease (AD). Muscarinic acetylcholine receptors (mAChRs) …

One of the consistent findings in the brains of Alzheimer's Disease (AD) patients is loss of
cholinergic function. The cholinergic approach to treatment of AD involves counteracting this …

Muscarinic acetylcholine receptors (mAChRs) are widely expressed in the CNS where they
control a variety of neuronal functions. Due to their roles in a number of CNS processes …

Muscarinic acetylcholine receptors (mAChRs) are G proteincoupled receptors (GPCRs) that
mediate the metabotropic actions of acetylcholine (ACh). There are five subtypes of mAChR …

Cholinergic deficit is a cardinal feature of Alzheimer's disease, and cholinesterase inhibitors
represent one of the most prominent means of mitigating this dysfunction. Cholinesterase …

The realization of the therapeutic potential of targeting the M1 muscarinic acetylcholine
receptor (mAChR) for the treatment of cognitive decline in Alzheimer's disease has …

The M1 muscarinic receptor (M1 mAChR), preserved in Alzheimer's disease (AD), is a
pivotal target that links major hallmarks of AD, eg cholinergic deficiency, cognitive …

The forebrain cholinergic system promotes higher brain function in part by signaling through
the M1 muscarinic acetylcholine receptor (mAChR). During Alzheimer's disease (AD), these …